AChE-IN-63 (Compound 5AD) serves as a selective inhibitor of hAChE, exhibiting an IC 50 value of 0.103 μM. Moreover, it inhibits hBChE and hBACE-1 with IC 50 values of 10 μM and 1.342 μM, respectively. AChE-IN-63 is effective in inhibiting Aβ aggregation and preventing the formation and deposition of Aβ1-42. It can effectively penetrate the blood-brain barrier and is orally bioavailable. This compound is primarily utilized in research related to Alzheimer's disease [1].

BCHE (human):10 μM, AChE (human):0.103 μM

AChE-IN-63 (5-20 μM; 48 h) inhibits the aggregation of Aβ1-42 in a concentration-dependent manner [1].

Administered orally in a single dose at 100 mg/kg, AChE-IN-63 did not exhibit toxicity or any abnormal reactions in Swiss albino mice [1]. In the scopolamine-induced Y-maze model, AChE-IN-63 at doses of 5-20 mg/kg (p.o.; 单剂量) significantly enhanced learning and memory abilities in mice with cognitive impairment, demonstrating notable antioxidative properties [1]. In the same animal model, the compound improved spontaneous alternation behavior while reducing AChE and MDA levels and increasing CAT levels at dosages of 5, 10, and 20 mg/kg [1].